Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

490
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

568
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

538
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

442
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

605
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
605
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

356
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
356

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Indications, protocols, and interpretation of cardiovascular imaging for the evaluation and management of athletes. A Clinical Consensus Statement of the European Association of Preventive Cardiology (EAPC) and the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC). Part 2-Cardiovascular Magnetic Resonance, Cardiac CT and Nuclear Imaging.

European heart journal. Cardiovascular Imaging·2026
Same author

Indications, protocols, and interpretation of cardiovascular imaging for the evaluation and management of athletes: a clinical consensus statement of the European Association of Preventive Cardiology (EAPC) and the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC), Part 2: Cardiovascular magnetic resonance, cardiac CT, and nuclear imaging.

European journal of preventive cardiology·2026
Same author

Unravelling the grey zone: submaximal-to-peak stress echocardiography enhances diagnostic accuracy in differentiating early dilated cardiomyopathy from physiological adaptation.

Echo research and practice·2026
Same author

Grey zone between physiological adaptation and cardiac disease in athletes: state of knowledge and future perspectives.

Heart (British Cardiac Society)·2026
Same author

Resting and exercise-induced occult hypertension and coronary atherosclerosis in male masters endurance athletes.

British journal of sports medicine·2026
Same author

Cardiac evaluation of paediatric athletes.

European heart journal·2026

Related Experiment Video

Updated: Feb 2, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Hypertrophic Cardiomyopathy in Athletes.

Aneil Malhotra1, Sanjay Sharma1

  • 1Cardiology Clinical and Academic Group, St. George's University of London London, UK.

European Cardiology
|November 13, 2018
PubMed
Summary
This summary is machine-generated.

Differentiating hypertrophic cardiomyopathy (HCM) from physiological left ventricular hypertrophy (LVH) in young athletes is crucial. Accurate diagnosis prevents sudden cardiac death (SCD) and guides sports participation decisions.

Keywords:
Athlete’s hearthypertrophic cardiomyopathyleft ventricular hypertrophysudden cardiac death

More Related Videos

A Neuroscientific Approach to the Examination of Concussions in Student-Athletes
11:32

A Neuroscientific Approach to the Examination of Concussions in Student-Athletes

Published on: December 8, 2014

13.2K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K

Related Experiment Videos

Last Updated: Feb 2, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
A Neuroscientific Approach to the Examination of Concussions in Student-Athletes
11:32

A Neuroscientific Approach to the Examination of Concussions in Student-Athletes

Published on: December 8, 2014

13.2K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K

Area of Science:

  • Cardiology
  • Sports Medicine
  • Genetics

Background:

  • Sudden cardiac death (SCD) in young individuals is a rare but devastating event.
  • Hypertrophic cardiomyopathy (HCM) is a leading cause of SCD in athletes under 35.
  • Distinguishing pathological HCM from physiological left ventricular hypertrophy (LVH) in athletes is challenging due to exercise-induced cardiac adaptations.

Purpose of the Study:

  • To review current literature to aid in differentiating physiological LVH from HCM in young athletes.
  • To highlight the importance of accurate diagnosis for athlete safety and management.
  • To provide insights into the clinical features of HCM in athletic populations.

Main Methods:

  • Review of existing studies comparing clinical findings in athletes with and without HCM.
  • Analysis of diagnostic tools used to differentiate between physiological and pathological cardiac hypertrophy.
  • Focus on emerging data regarding the clinical presentation of HCM in athletes.

Main Results:

  • Physiological LVH in athletes can mimic HCM, complicating diagnosis.
  • Subtle clinical features are key to differentiating between the two conditions.
  • Athletes with HCM may present differently than sedentary individuals.

Conclusions:

  • Accurate differentiation of LVH from HCM is critical for young athletes.
  • Misdiagnosis can lead to inappropriate restrictions from sports or, conversely, place athletes at risk of SCD.
  • Further research focusing on HCM in athletes is needed to refine diagnostic strategies.